Boehringer Ingelheim's survodutide (a dual GLP-1/glucagon receptor agonist) has posted remarkable Phase 2b data for MASH (metabolic dysfunction-associated steatohepatitis), and I think this deserves serious discussion.

Key results from the Phase 2b trial published in NEJM:^[1]

• 83% of participants on the highest dose achieved MASH resolution (vs. 18% placebo)
• 65% achieved fibrosis improvement by ≥1 stage
• 52% achieved BOTH MASH resolution AND fibrosis improvement
• Mean weight loss of ~18% at 48 weeks

"These histological improvements are among the most robust reported for any pharmacological intervention in MASH to date."
— Sanyal AJ, et al. N Engl J Med. 2024.

For context, the recently approved MASH drug resmetirom (Rezdiffra) showed MASH resolution in ~26% and fibrosis improvement in ~24%. Survodutide's numbers are in a completely different league.

The SYNCHRONIZE Phase 3 program is now underway. If these results hold up, survodutide could redefine MASH treatment.

[1] Sanyal AJ, et al. Survodutide for MASH. N Engl J Med. 2024.

Those histology numbers are genuinely staggering. 83% MASH resolution is almost unbelievable compared to what we've seen before. But I want to flag some important caveats:

1. This was a Phase 2b trial with relatively small sample sizes per arm. Phase 3 results often regress toward the mean.
2. The 18% weight loss is doing a LOT of heavy lifting. Weight loss alone is the most effective intervention for MASH. How much of the histological improvement is direct drug effect vs. indirect effect of massive weight loss?
3. Biopsy-based endpoints are inherently variable. Sampling error in liver biopsies is well-documented and can inflate response rates.

I'm optimistic but cautiously so. The SYNCHRONIZE Phase 3 data will be definitive.

To address the "is it just the weight loss?" question, we can look at the dose-response relationship. The histological improvements with survodutide were greater than what you'd expect from weight loss alone based on historical data:

• In lifestyle intervention studies, ~10% weight loss typically yields MASH resolution in ~50-60% of patients
• Survodutide at the highest dose showed 83% resolution with ~18% weight loss
• Even the lower-dose arms, which produced less weight loss, showed histological improvements exceeding what weight loss alone would predict

This suggests a direct hepatic effect of glucagon receptor agonism beyond what's attributable to weight loss. The GCG component is likely driving hepatic lipid oxidation and reducing hepatic inflammation through receptor-mediated pathways in hepatocytes.

I was diagnosed with MASH last year (F2 fibrosis on biopsy) and my hepatologist basically told me there aren't great drug options yet. I've lost about 8% body weight on semaglutide and my ALT has normalized, but we haven't repeated the biopsy yet.

The idea that a drug could achieve 83% MASH resolution is incredible from a patient perspective. Do we know if survodutide would be indicated for MASH specifically, or only for obesity/diabetes patients who also have MASH?

The SYNCHRONIZE program is specifically studying MASH as the primary indication, not just weight loss. Boehringer is going for a MASH-specific approval, which makes sense strategically — the MASH market is less crowded than the obesity market, and the unmet need is enormous.

That said, the weight loss is a bonus for patients. Most MASH patients are also overweight/obese, so a drug that addresses both is highly valuable. The dual GLP-1/GCG mechanism of survodutide is well-suited for this because:

• GLP-1 drives weight loss and improves insulin sensitivity
• GCG drives hepatic fat oxidation, reducing liver fat directly

The key competition in MASH will be against retatrutide (Lilly's TRIUMPH-4 trial) and tirzepatide (SYNERGY-NASH trial). Both are also showing impressive liver data. This is going to be a very competitive space in the next 2-3 years.